Prostatitis, Pelvic Pain and Interstitial Cystitis

The core problem: the prostate is a hard place to reach

Curing a prostate infection is a pharmacokinetics problem before it is a microbiology problem. The prostate behaves like a sanctuary site. A lipid-rich epithelial barrier separates prostatic fluid from blood, and prostatic secretions sit at a relatively acidic pH. To cross that barrier and accumulate inside, a drug needs to be lipophilic (fat-soluble enough to slip through membranes) and to favour partitioning into the acidic compartment — a weak base that becomes trapped there as it picks up a proton. Two drug groups fit this profile beautifully: the fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin) and trimethoprim. Both are lipophilic and achieve prostatic concentrations well above their blood levels, which is exactly why they dominate prostatitis treatment. This is the tissue-penetration principle taught in full in the Antimicrobials section — the same logic that explains why some antibiotics reach the CSF or bone and others do not.

The mirror image is the beta-lactams — penicillins and most cephalosporins. They are hydrophilic and poorly lipid-soluble, so in a healthy prostate they barely get in, and monotherapy with them fails. There is one important exception written into the pathophysiology: acute inflammation. When the prostate is acutely inflamed, its barrier becomes leaky and even poorly-penetrating drugs can flood in — which is why a severely septic man with acute prostatitis may initially respond to intravenous broad-spectrum cover. But as the inflammation settles the barrier reseals, so the definitive oral course must switch to a penetrating agent to finish the job.

Acute bacterial prostatitis: hit hard, penetrate, and treat long

The typical organisms are the Gram-negative uropathogens — Escherichia coli and other coliforms — so empirical cover targets them. A systemically unwell, toxic man is admitted for intravenous therapy (a broad-spectrum agent such as a cephalosporin, often with gentamicin) until he defervesces; a less unwell man can start oral therapy directly. Either way the definitive treatment converges on a prostate-penetrating oral drug — a fluoroquinolone (ciprofloxacin) or trimethoprim — continued for a prolonged course, typically 2–4 weeks. The long duration is not habit: it reflects the difficulty of sterilizing prostatic tissue and the real risk that a half-treated acute infection smoulders into chronic bacterial prostatitis or walls off into a prostatic abscess.

Two practical cautions ride along with the fluoroquinolones. Fluoroquinolones are superb here, but they carry class-specific safety baggage worth remembering: tendinopathy and tendon rupture (especially the Achilles, and more so in older patients or those on corticosteroids), QT-interval prolongation, aortic aneurysm risk, and rare but serious neuropsychiatric and peripheral-neuropathy effects — enough that regulators now advise reserving them for infections where the benefit clearly justifies use. Prostatitis is exactly such an indication. Trimethoprim is the main alternative; it raises serum creatinine (by blocking its tubular secretion, not by true renal injury) and can raise potassium, and it should be avoided in the first trimester of pregnancy as a folate antagonist — though that particular caution rarely bears on a male prostate.

Chronic bacterial prostatitis: long courses and easier voiding

Chronic bacterial prostatitis is the picture of recurrent urinary tract infections in a man, driven by the same organism relapsing from a prostatic reservoir the antibiotic never fully cleared. The answer is more of the same principle, taken further: a prolonged 4–6 week course of a prostate-penetrating antibiotic (a fluoroquinolone or trimethoprim), long enough to sterilize the tissue rather than merely knock back the urine. Alongside the antibiotic, an alpha-blocker such as tamsulosin is added to ease voiding — relaxing the smooth muscle of the bladder neck and prostate lowers outflow resistance, improves emptying, and reduces the reflux of infected urine back into prostatic ducts. That alpha-blockade is the same pharmacology developed in full in the BPH chapter, borrowed here for a different purpose.

Chronic pelvic pain syndrome: the common one, and usually NOT bacterial

This is the diagnosis most men with "prostatitis" actually have — and the one most often mistreated. Chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS) is by far the commonest category, and the crucial fact is that it is usually non-bacterial: cultures are negative, and repeated antibiotics achieve nothing but side effects and resistance. Persistent pelvic, perineal or ejaculatory pain with variable urinary symptoms, in the absence of a demonstrable organism, calls for a multimodal approach rather than another prescription for ciprofloxacin. The pillars are: an alpha-blocker (tamsulosin) to ease voiding symptoms; simple analgesia and NSAIDs for the inflammatory-type pain; and pelvic-floor physiotherapy, because much of the pain is muscular and myofascial rather than glandular. Antibiotics are not banned outright, but they are confined to a single defined trial in antibiotic-naïve patients — if there is no response, they are stopped, not recycled indefinitely.

When the pain persists and behaves like nerve pain — burning, radiating, disproportionate, with central sensitization — the pharmacology shifts entirely onto the neuropathic-pain shelf. A low-dose tricyclic such as amitriptyline, or a gabapentinoid such as pregabalin or gabapentin, becomes the mainstay. These are not analgesics in the ordinary sense; they damp down abnormal neuronal firing and the amplified central processing of pain, and their mechanisms are taught in full in the Central Nervous System section (amitriptyline blocking monoamine reuptake and sodium channels; pregabalin and gabapentin binding the α2δ subunit of voltage-gated calcium channels to reduce excitatory neurotransmitter release). Reframing chronic pelvic pain as a neuropathic, centrally-driven condition — not a stubborn infection — is the single most useful shift a clinician can make.

Interstitial cystitis / bladder pain syndrome: stepwise and often humbling

Interstitial cystitis (IC), also called bladder pain syndrome, is chronic bladder pain, pressure and urinary urgency and frequency in the absence of infection — far more common in women than men. Its pharmacology is genuinely stepwise and, honestly, often disappointing, so expectations should be set realistically. First-line is conservative: identifying and avoiding dietary triggers (classically caffeine, alcohol, acidic and spicy foods), bladder retraining, and stress management. Oral options include pentosan polysulfate sodium (PPS), whose proposed mechanism is to restore the bladder's protective glycosaminoglycan (GAG) layer — the mucus lining that normally shields the urothelium from irritant urine — and amitriptyline, exploiting both its neuropathic-pain and antimuscarinic (bladder-calming) actions. Some patients gain from antihistamines, on the theory that mast-cell activation contributes to the inflammation.

One drug in this list carries a safety signal students should file away. Pentosan polysulfate has been linked to a distinctive pigmentary maculopathy — a retinal disorder causing visual changes with long-term, cumulative use — so patients on it need baseline and periodic ophthalmological review. This is a neat cross-link to the Ophthalmology chapter, alongside the other drugs with retinal or optic toxicity (hydroxychloroquine, ethambutol, vigabatrin). When oral therapy is insufficient, treatment steps up to intravesical instillations — medication placed directly into the bladder to act locally and spare the body a systemic dose. Common instillates include DMSO (dimethyl sulfoxide), hyaluronic acid and heparin (both aiming to replenish the GAG layer), and local anaesthetic. The guiding rule throughout is restraint: avoid the reflexive long courses of antibiotics that these patients so often accumulate, because there is no infection to treat and every course adds risk without benefit.

Epididymo-orchitis: treat by the likely organism

A related scrotal infection completes the picture, and here the antibiotic choice turns entirely on age and sexual history, because that predicts the organism. In younger, sexually active men, epididymo-orchitis is usually a sexually transmitted infection — Chlamydia trachomatis or Neisseria gonorrhoeae — so treatment follows STI lines: doxycycline (covering chlamydia) plus a single dose of intramuscular ceftriaxone (covering gonorrhoea). This dovetails with the STI chapter, where the same doxycycline-and-ceftriaxone backbone recurs. In older men, and those with recent urinary instrumentation or bladder-outflow obstruction, the cause is more likely an enteric UTI organism ascending from the urinary tract, so a fluoroquinolone (which conveniently also penetrates the genital tract well) is the sensible choice. Matching the antibiotic to the probable bug, rather than reflexively giving one drug to all comers, is the recurring discipline of this whole cluster.